Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study

Objective The objective of this study was to evaluate whether hydroxychloroquine (HCQ) therapy effects subjective and/or objective complaints and salivary flow rates of patients with primary Sjögren's syndrome (PSS). Study design Thirty women recently diagnosed with PSS, scheduled for HCQ treat...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oral surgery, oral medicine, oral pathology, oral radiology and endodontics oral medicine, oral pathology, oral radiology and endodontics, 2010-07, Vol.110 (1), p.62-67
Hauptverfasser:	Çankaya, Hulya, DDS, PhD, Alpöz, Esin, DDS, PhD, Karabulut, Gonca, MD, PhD, Güneri, Pelin, DDS, PhD, Boyacıoglu, Hayal, PhD, Kabasakal, Yasemin, MD, PhD
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Burning Mouth Syndrome - drug therapy Burning Mouth Syndrome - psychology Cheilitis - drug therapy Cheilitis - psychology Cholinesterase Inhibitors - therapeutic use Deglutition - physiology Dentistry Enzyme Inhibitors - therapeutic use Female Follow-Up Studies Humans Hydroxychloroquine - therapeutic use Mastication - physiology Medical sciences Middle Aged Otorhinolaryngology. Stomatology Patient Satisfaction Pharmacology. Drug treatments Saliva - drug effects Saliva - secretion Secretory Rate - drug effects Sjogren's Syndrome - drug therapy Sjogren's Syndrome - psychology Surgery Treatment Outcome Xerostomia - drug therapy Xerostomia - psychology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Objective The objective of this study was to evaluate whether hydroxychloroquine (HCQ) therapy effects subjective and/or objective complaints and salivary flow rates of patients with primary Sjögren's syndrome (PSS). Study design Thirty women recently diagnosed with PSS, scheduled for HCQ treatment (400 mg daily), participated and were clinically examined before initiation of 30 weeks of HCQ treatment. During baseline evaluation, both the objective and/or subjective oral findings were recorded. Unstimulated (uSFR) and stimulated salivary flow rates (sSFR) were determined. After initiation of HCQ treatment, study parameters were assessed at 6, 12, 18, 24, and 30 weeks. Each patient served as her own control; measurements of the baseline and control times were analyzed by ANOVA. Results uSFR values increased significantly with HCQ treatment, but sSFR values, objective and/or subjective complaints did not change considerably. Conclusion A positive impact of 30 weeks of HCQ treatment only on uSFRs of SS patients was revealed.
ISSN:	1079-2104 1528-395X
DOI:	10.1016/j.tripleo.2010.02.032